PDF(Pubmed)
Abstract：
BACKGROUND: Deregulation of immune checkpoint is an important point in cancer evolution as well as patients outcome. T-cells is an important arm in immunity against cancer. This study aimed to assess CTLA4/LAG3 expression on different T-cell subsets and its effect on disease outcome.
METHODS: This study included 81 newly diagnosed Egyptian adult AML patients. For each one of the patients CTLA4/ LAG3 expression on T-cell subsets was identified by flowcytometry before start of induction chemotherapy.
RESULTS: Total CD3 count in AML patients was lower than control. LAG3 expression were significantly higher in total CD3, T-cell subsets (CD4, CD8) as compared to healthy control. Moreover, co-expression of LAG3/CTLA4 on T-cell subsets were significantly higher in AML as compared to healthy control . NPM-/ FLT3+ was significantly associated with high LAG3 expression in T-cells subsets as compared to other molecular subtypes. Shorter OS, DFS were significantly associated with higher expression of LAG3 on T-cells subsets as compared to patients harbor low expression. COX regression analysis revealed that high expression of CD3/LAG3, CD4/LAG3, CD8/LAG4, CD3/CTLA4/LAG3 were considered a poor prognostic risk factor.
CONCLUSIONS: High LAG3/CTLA4 expression could predict AML Patients\' outcome Conclusion: Our findings indicated that high expression of LAG3/CTL4 on T cells subsets identify a subgroup of AML patients with poor prognosis.
METHODS: This study included 81 newly diagnosed Egyptian adult AML patients. For each one of the patients CTLA4/ LAG3 expression on T-cell subsets was identified by flowcytometry before start of induction chemotherapy.
RESULTS: Total CD3 count in AML patients was lower than control. LAG3 expression were significantly higher in total CD3, T-cell subsets (CD4, CD8) as compared to healthy control. Moreover, co-expression of LAG3/CTLA4 on T-cell subsets were significantly higher in AML as compared to healthy control . NPM-/ FLT3+ was significantly associated with high LAG3 expression in T-cells subsets as compared to other molecular subtypes. Shorter OS, DFS were significantly associated with higher expression of LAG3 on T-cells subsets as compared to patients harbor low expression. COX regression analysis revealed that high expression of CD3/LAG3, CD4/LAG3, CD8/LAG4, CD3/CTLA4/LAG3 were considered a poor prognostic risk factor.
CONCLUSIONS: High LAG3/CTLA4 expression could predict AML Patients\' outcome Conclusion: Our findings indicated that high expression of LAG3/CTL4 on T cells subsets identify a subgroup of AML patients with poor prognosis.
摘要：
背景：免疫检查点的放松调节是癌症演变以及患者预后的重要方面。T细胞是癌症免疫的重要组成部分。本研究旨在评估CTLA4/LAG3在不同T细胞亚群上的表达及其对疾病预后的影响。
方法：本研究纳入了81例新诊断的埃及成年AML患者。对于每个患者,在开始诱导化疗之前通过流式细胞术鉴定T细胞亚群上的CTLA4/LAG3表达。
结果：AML患者的总CD3计数低于对照组。与健康对照相比，总CD3，T细胞亚群（CD4，CD8）中的LAG3表达明显更高。此外，与健康对照相比,在AML中T细胞亚群上LAG3/CTLA4的共表达显著更高。与其他分子亚型相比，NPM-/FLT3与T细胞亚群中的高LAG3表达显着相关。较短的操作系统，与具有低表达的患者相比,DFS与T细胞亚群上LAG3的较高表达显著相关。COX回归分析显示CD3/LAG3、CD4/LAG3、CD8/LAG4、CD3/CTLA4/LAG3的高表达被认为是预后不良的危险因素。
结论：LAG3/CTLA4高表达可预测AML患者的预后结论：我们的研究结果表明，T细胞亚群上LAG3/CTL4的高表达可确定预后不良的AML患者亚群。
方法：本研究纳入了81例新诊断的埃及成年AML患者。对于每个患者,在开始诱导化疗之前通过流式细胞术鉴定T细胞亚群上的CTLA4/LAG3表达。
结果：AML患者的总CD3计数低于对照组。与健康对照相比，总CD3，T细胞亚群（CD4，CD8）中的LAG3表达明显更高。此外，与健康对照相比,在AML中T细胞亚群上LAG3/CTLA4的共表达显著更高。与其他分子亚型相比，NPM-/FLT3与T细胞亚群中的高LAG3表达显着相关。较短的操作系统，与具有低表达的患者相比,DFS与T细胞亚群上LAG3的较高表达显著相关。COX回归分析显示CD3/LAG3、CD4/LAG3、CD8/LAG4、CD3/CTLA4/LAG3的高表达被认为是预后不良的危险因素。
结论：LAG3/CTLA4高表达可预测AML患者的预后结论：我们的研究结果表明，T细胞亚群上LAG3/CTL4的高表达可确定预后不良的AML患者亚群。
